...
首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice
【24h】

Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice

机译:自转霉菌双峰PDX1-FOXP3蛋白升降胰岛素分泌物和抑制型糖尿病小鼠1型促进Tregs

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Type 1 diabetes (T1D) is characterized by massive destruction of insulin-producing β cells by autoreactive T lymphocytes, arising via defective immune tolerance. Therefore, effective anti-T1D therapeutics should combine autoimmunity-preventing and insulin production-restoring properties. We constructed a cell-permeable PDX1-FOXP3-TAT fusion protein (FP) composed of two transcription factors: forkhead box P3 (FOXP3), the master regulator of differentiation and functioning of self-tolerance-promoting Tregs, and pancreatic duodenal homeobox-1 (PDX1), the crucial factor supporting β cell development and maintenance. The FP was tested in?vitro and in a non-obese diabetic mouse T1D model. In?vitro, FP converted naive CD4 + T?cells into a functional “Treg-like” subset, which suppressed cytokine secretion, downregulated antigen-specific responses, and curbed viability of diabetogenic effector cells. In hepatic stem-like cells, FP potentiated endocrine transdifferentiation, inducing expression of Insulin2 and other β lineage-specific genes. In?vivo, FP administration to chronically diabetic mice triggered (1) a significant elevation of insulin and C-peptide levels, (2) the formation of insulin-containing cell clusters in livers, and (3) a systemic anti-inflammatory shift (higher Foxp3 + CD4 + CD25 + T?cell frequencies, elevated rates of IL-10-producing cells, and reduced rates of IFN-γ-secreting cells). Overall, in accordance with its design, PDX1-FOXP3-TAT FP delivered both Treg-stabilizing anti-autoimmune and de novo insulin-producing effects, proving its anti-T1D therapeutic potential. Amatya et?al. devised an innovative anti-T1D combination therapy with a self-transducible molecule composed of two transcription factors, Foxp3 and Pdx1, fused to protein transduction domain. The resultant protein promotes transdifferentiation of hepatocytes into insulin-producing cells (through Pdx1) and increases frequencies of functional Tregs (through Foxp3) in NOD mice.
机译:1型糖尿病(T1D)的特征在于通过自动反应性T淋巴细胞大量破坏胰岛素产生的β细胞,通过缺陷免疫耐受性而产生。因此,有效的抗T1D治疗剂应结合自身免疫和胰岛素生产恢复性能。我们构建了由两种转录因子组成的细胞渗过的PDX1-FOXP3-TAT融合蛋白(FP):FORKHEAD箱P3(FOXP3),促进自耐受促进Tregs的分化和运作的主调节器,以及胰腺十二指肠Homeobox-1 (PDX1),支持β细胞开发和维护的关键因素。 FP在体外和非肥胖糖尿病小鼠T1D模型中进行了测试。在体外,FP转化为纯度CD4 + T?细胞进入官能的“Treg样”子集中,其抑制细胞因子分泌,下调的抗原特异性反应,并抑制糖尿病效应细胞的活力。在肝脏干细胞中,FP调节内分泌转移细胞,诱导胰岛素2的表达和其他β谱系特异性基因。在α体内,FP给慢性糖尿病小鼠施用(1)胰岛素和C-肽水平的显着升高,(2)在肝脏中形成含胰岛素的细胞簇,(3)全身抗炎转移(更高的Foxp3 + CD4 + CD25 + T?细胞频率,IL-10产生细胞的升高,以及IFN-γ-分泌细胞的速率降低)。总体而言,按照其设计,PDX1-FOXP3-TAT FP通过Treg稳定的抗自身免疫和De Novo胰岛素产生的效果,证明其抗T1D治疗潜力。 amatya等。用由两个转录因子,FoxP3和PDX1组成的自转型分子设计了一种创新的抗T1D组合疗法,融合到蛋白质转导域。得到的蛋白质促进肝细胞转化为胰岛素 - 产生细胞(通过PDX1),并增加Nod小鼠中功能性Tregs(通过Foxp3)的频率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号